Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

e second quarter of 2011.  The decrease reflects lower costs as a result of the second quarter branded division restructuring, as well as lower legal and share-based compensation expenses.

Cash and cash equivalents and marketable securitiesThe aggregate balance as of September 30, 2011 was approximately $256.8 million, after $157.6 million in payments during the quarter for previously announced AWP litigation settlements.

Product and Pipeline UpdateIn August, Par Pharmaceutical Companies entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash.  The transaction is expected to close by year-end.

In October, Par Pharmaceutical acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon.  Par now owns the ANDAs of fentanyl citrate lozenges, a generic version of Actiq®, and cyclobenzaprine ER capsules, the generic version of Amrix®, as well as the U.S. rights to market modafinil tablets, the generic version of Provigil®.  Par is currently shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva.

In October, Par Pharmaceutical began shipping all strengths of olanzapine orally disintegrating tablets, the generic version of Lilly's Zyprexa Zydis®.  According to IMS Health data, annual sales in the U.S. of Zyprexa Zydis are approximately $360 million.

Par Pharmaceutical, along with third-party partners, currently has approximately 32 ANDAs pending with the FDA, 13 of which it believes to be first-to-file opportunities.

Conference CallThe Company will host a conference call and live webcast today, Wednesday, November 2, 2011 at 9:00 AM EDT to review results for the third quarter 2011.  
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical ... in opioid antagonists, announced today that it has ... respect to its naloxone-based opioid overdose reversal nasal ... received an additional commitment from the National Institute ... Institutes of Health ("NIH"), to fund a second ...
(Date:7/23/2014)... July 23, 2014 This September leading clinicians ... Las Vegas for DOCtalk 2014 ... author, forward thinker and private practitioner Dr. David ... to candidly discuss clinical and practice management efficiency and ... a unique opportunity to welcome fresh thinking and join ...
(Date:7/23/2014)... 23, 2014 Global healthcare company ... facing currency headwinds, increased price competition and supply disruptions ... Andrew Witty points out that the company is very ... reason to be confident about long-term prospects as well ... CFO Simon Dingemans adds that ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 32014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3
(Date:7/23/2014)... (July 23, 2014) Statins, a class of drugs ... patient,s risk of developing Barrett,s esophagus, according to a ... , the official journal of the American Gastroenterological Association. ... with statin use. , "Patients who received statins had ... Barrett,s esophagus compared to non-users," said study author Hashem ...
(Date:7/23/2014)... With cloud storage fast replacing traditional ... LeaseQ announced that that despite the lack of ... still see robust growth in computer hardware and ... technology equipment leasing, visit:, https://www.leaseq.com/computer-equipment-leasing , ... quoted as saying, “Although the growth of server ...
(Date:7/23/2014)... Hill, FL (PRWEB) July 23, 2014 The ... percent reduction in prescription drug deaths from 2010 to 2012. ... infamous for its minimal monitoring of access to some of ... the wrong hands. Florida’s law enforcement launched an initiative ... now nearly nonexistent compared to the 65 that existed in ...
(Date:7/23/2014)... 23, 2014 On July 21, 2014, My ... advocate Jack Tracey for an episode that spoke about the ... Deierlein asks Tracey to talk some about the formation of ... its mission, it was started right here in Charleston, originally ... was to help survivors of sexual abuse. Their purpose has ...
(Date:7/23/2014)... Five years ago, when the SSM St. ... options for babies diagnosed with a medical condition before birth. ... country for innovative fetal therapies. Since then, nearly 1,000 families ... for their babies in the womb, and the team has ... “A number of the babies we see are facing life-threatening ...
Breaking Medicine News(10 mins):Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2
... flu at the weekend, taking the death toll in the country ... said Monday . ,Indonesia has seen its toll from ... confirmed human deaths occurred here. ,"A boy who died ... positively infected," Ningrum, from the ministry's National Bird Flu Information Centre, ...
... Dengue fever killed 30 people in Myanmar in the first six ... latest country in the region to experience a surge in ... ministry official, told the weekly Myanmar Times newspaper that the number ... of this year there have been about 3,000 cases of the ...
... milk into a skin-care product that would wipe away wrinkles ... ,The government's team of camel researchers, which has already ... has found cosmetic properties in the hardy mammal's milk. ... to a hospital's skin department to study it on 20 ...
... demonstrated conclusively that a specific protein and its signaling ... essential to the creation and repair of the brains ... mouse models points the way to developing treatments or ... repair in children and adults. The paper will be ...
... make real breakthroughs in childrens medicine if they include children ... ,Professor John Warner was speaking today at the opening of ... to paediatric clinical research. ,The unit is run ... and it is based next to the hospitals paediatric wards ...
... Biology Laboratory (EMBL) and the University of Michigan have ... kidney disease ,In the current online ... the gene cause nephronopthisis (NPHP) in humans and mice. ... childhood that leads to kidney failure requiring organ transplantation. ...
Cached Medicine News:Health News:Indonesia Confirms 81st Bird Flu Death 2Health News:Specific Protein is Instrumental in Myelination 2Health News:Specific Protein is Instrumental in Myelination 3Health News:Experts Need to Include Children in Research 2Health News:New Therapies for Kidney Diseases 2
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
5.5 pointed curved blade. Octagonal handle....
3 mm curved blade. Round handle....
8 mm downcutting Royce blade. Angled shaft. 60 mm from angle to tip....
Medicine Products: